You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
藥明康德(603259.SH)子公司擬認購Mission BioCapital 300萬美元份額
格隆匯 12-22 16:44

格隆匯12月22日丨藥明康德(603259.SH)公佈,2020年12月22日,公司全資子企業WuXi PharmaTech Healthcare Fund I L.P.(以下簡稱“WuXi Fund I”)與Mission BioCapital V LP(以下簡稱“投資基金”或“Mission BioCapital”)(由Mission BioCapital V GP LLC(以下簡稱“普通合夥人”)代表簽署)、普通合夥人簽署Subscription Agreement(以下簡稱“認購協議”),約定由WuXi Fund I認繳投資基金的300萬美元份額,約佔已募集投資基金份額的1.8%(截至公告日,投資基金已募集資金1.66億美元,計劃募集2.50億美元,WuXi Fund I在投資基金中持有的基金份額比例將隨着投資基金的後續募集而稀釋)。WuXi Fund I於本公告日以自有資金支付15萬美元投資款,後續將繼續以自有資金根據合夥協議的要求履行投資款的支付義務。

Mission BioCapital的投資將主要針對美國早期生命科學和生物技術企業。公司認為,Mission BioCapital的管理團隊在該投資領域具有豐富的投資經驗和廣泛的業內資源,其實驗室網絡共享模式能夠提高資本利用效率並降低風險。公司以較低比例投資Mission BioCapital,作為其有限合夥人,一方面有望使公司在投資風險可控的前提下,獲得風險投資相關的財務收益;另一方面,Mission BioCapital投資所針對的早期生命科學和生物技術企業是公司重要的潛在長尾客户羣體,該投資有助於公司進一步深耕美國市場,擴展長尾客户羣體,支持公司主營業務的發展。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account